Page 106 - Read Online

Liu et al. Hepatoma Res 2020;6:42 I http://dx.doi.org/10.20517/2394-5079.2020.25 Page 11 of 12

for further study. J Hepatol 2019;70:521-30.
52. Yang J, Trépo E, Nahon P, Cao Q, Moreno C, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across
various etiologies and severity of underlying liver diseases. Int J Cancer 2019;144:533-44.
53. Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model
prediction in patients with cirrhosis. J Hepatol 2013;58:312-8.
54. Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and liver disease. Transl Res 2011;157:241-52.
55. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of
hepatocellular carcinoma. Nat Mater 2017;16:1155-61.
56. Yu JH, Suh YJ, Jin YJ, Yeo NY, Jang JW, et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B
patients receiving entecavir/tenofovir. Eur J Gastroenterol Hepatol 2019;31:865-72.
57. Whitfield JB, Schwantes-An TH, Cordell HJ, Darlay R, Masson S, et al. Can genotyping predict risk of alcohol-related cirrhosis in high-
risk drinkers? Hepatology 2019;70:171A-2.
58. Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis
2015;35:270-90.
59. Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology
2016;150:1728-44.e7.
60. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018;19:581-90.
61. Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, et al. Breast cancer risk from modifiable and nonmodifiable risk factors among
white women in the United States. JAMA Oncol 2016;2:1295-302.
62. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, et al. BOADICEA: a comprehensive breast cancer risk prediction model
incorporating genetic and nongenetic risk factors. Genet Med 2019;21:1708-18.
63. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2015;26:v8-30.
64. Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development
of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am J Gastroenterol 2018;113:1475-83.
65. Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, et al. Novel hepatocellular carcinoma molecules with prognostic and therapeutic
potentials. World J Gastroenterol 2014;20:1268-88.
66. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma.
Hepatology 2011:483-90.
67. Sieghart W, Wang X, Schmid K, Pinter M, König F, et al. Osteopontin expression predicts overall survival after liver transplantation for
hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011;54:89-97.
68. Zhou SL, Zhou ZJ, Hu ZQ, Song CL, Luo YJ, et al. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a
risk factor for early recurrence. J Hepatol 2019;71:1152-63.
69. Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: an update. World J Gastroenterol 2016;22:9069-95.
70. Ye QH, Qin LX, Forgues M, He P, Kim JW, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene
expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
71. Wahid B, Ali A, Rafiqe S, Idrees M. New insights into the epigenetics of hepatocellular carcinoma. Biomed Res Int 2017;2017:1609575.
72. Toh TB, Lim JJ, Chow EK. Epigenetics of hepatocellular carcinoma. Clin Trans Med 2019;8:13.
73. Lozano-Rosas MG, Chávez E, Aparicio-Cadena AR, Velasco-Loyden G, Sánchez VC. Mitoepigenetics and hepatocellular carcinoma.
Hepatoma Res 2018;4:19.
74. Méndez-Sánchez N, Valencia-Rodríguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, et al. The mechanism of dysbiosis in alcoholic
liver disease leading to liver cancer. Hepatoma Res 2020;6:5.
75. Neuman MG, Seitz HK, French SW, Malnick S, Tsukamoto H, et al. Alcoholic-hepatitis, links to brain and microbiome: mechanisms,
clinical and experimental research. Biomedicines 2020;8:63.
76. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
77. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, et al. Identification of an immune-specific class of hepatocellular
carcinoma, based on molecular features. Gastroenterology 2017;153:812-26.
78. Wheelar DA, Roberts LR. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327-
41.e23.
79. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, et al. Histological subtypes of hepatocellular carcinoma are related to gene
mutations and molecular tumour classification. J Hepatol 2017;67:727-38.
80. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, et al. Prospective genotyping of hepatocellular carcinoma: clinical
implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019;25:2116-26.
81. Theise ND. Histopathology of alcoholic liver disease. Clin Liver Dis 2013;2:64-7.
82. Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol 2019;70:294-304.
83. Ganne-Carrie N, Layese R, Bourcier V, Cagnot C, Marcellin P, et al. Nomogram for individualized prediction of hepatocellular carcinoma
occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology 2016;64:1136-47.
84. Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol
2015;63:722-32.
85. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.